MGP
PBYI icon

Metis Global Partners’s Puma Biotechnology PBYI Stock Holding History

Metis Global Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Sell
25,264
-17,322
-41% -$112K ﹤0.01% 700
2025
Q4 		$253K Sell
42,586
-13,212
-24% -$70.2K 0.01% 677
2025
Q3 		$296K Hold
55,798
– – 0.01% 670
2025
Q2 		$191K Buy
55,798
+13,040
+30% +$41.6K ﹤0.01% 728
2025
Q1 		$127K Buy
42,758
+3,231
+8% +$10.1K ﹤0.01% 769
2024
Q4 		$121K Hold
39,527
– – ﹤0.01% 768
2024
Q3 		$101K Hold
39,527
– – ﹤0.01% 772
2024
Q2 		$129K Hold
39,527
– – ﹤0.01% 741
2024
Q1 		$209K Buy
+39,527
New +$213K 0.01% 710

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Metis Global Partners's PBYI Position: Q1 2026 in Review

Metis Global Partners reduced its Puma Biotechnology (PBYI) stake by 41% in Q1 2026, selling an estimated $112K and leaving 25,264 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #700.

Metis Global Partners first reported a position in PBYI in Q1 2024 and has held it in 9 quarters since. The position peaked at $296K in Q3 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Metis Global Partners held 25,264 shares of Puma Biotechnology worth $161K as of Q1 2026.
  • Metis Global Partners sold 17,322 Puma Biotechnology shares in Q1 2026, an estimated $112K.
  • Puma Biotechnology made up ﹤0.01% of Metis Global Partners's portfolio in Q1 2026, its #700 holding.
  • Metis Global Partners first reported a position in Puma Biotechnology in Q1 2024 and has held it in 9 quarters since.
  • Metis Global Partners's Puma Biotechnology position peaked at $296K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Metis Global Partners's 13F filing for Q1 2026, filed 7 May 2026.